While tumor budding was not prognostic for disease-free survival (DFS) in either group, it was prognostic for worse DFS in the sub-group of ER-positive and HER2-negative patients with an intermediate Oncotype Dx score. This evidence concerns the gene ERBB2 and neoplasm.